Authors
Howell, AnthonyAffiliation
CRC Department of Medical Oncology, Christie Hospital NHS Trust, M20 4BX, Manchester, UK. maria.parker@christie-tr.nwest.nhs.ukIssue Date
2000-09
Metadata
Show full item recordAbstract
Anti-oestrogen therapy, tamoxifen in particular, has revolutionised the treatment of breast cancer. However, the partial agonist activity of tamoxifen is associated with an increased risk of endometrial cancer and the acquisition by patients of tamoxifen-resistance. In an attempt overcome these negative aspects of tamoxifen therapy, 'pure' anti-oestrogens have been developed and are currently being investigated for the treatment of breast cancer.Citation
Faslodex (ICI 182780). an oestrogen receptor downregulator. 2000, 36 Suppl 4:S87-8 Eur. J. CancerJournal
European Journal of CancerDOI
10.1016/S0959-8049(00)00241-0PubMed ID
11056334Type
ArticleLanguage
enISSN
0959-8049ae974a485f413a2113503eed53cd6c53
10.1016/S0959-8049(00)00241-0
Scopus Count
Collections
Related articles
- Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.
- Authors: Robertson JF
- Issue date: 2001 Dec
- ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.
- Authors: Robertson JF
- Issue date: 2001 Nov
- Pure oestrogen antagonists for the treatment of advanced breast cancer.
- Authors: Howell A
- Issue date: 2006 Sep
- ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
- Authors: Howell A, Osborne CK, Morris C, Wakeling AE
- Issue date: 2000 Aug 15
- Selective oestrogen receptor downregulator.
- Authors: Howell A
- Issue date: 2002 Nov